Anticorpo Monoclonal Anti-ICOS MEDI-570 no Tratamento de Pacientes com Linfoma Periférico de Células T Recidivante ou Refratário Variante Folicular ou Linfoma Angioimunoblástico de Células T
Um estudo de Fase I do MEDI-570 em pacientes com variante folicular de linfoma de células T periférico recidivante/refratário (PTCL) e linfoma de células T angioimunoblástico (AITL)
This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.
Visão geral do estudo
Status
Status
Condições
Condições
- Linfoma Folicular Grau 1 Recorrente
- Linfoma folicular de grau 2 recorrente
- Linfoma não Hodgkin cutâneo primário avançado de células T
- Linfoma Folicular Grau 3a Recorrente
- Linfoma não Hodgkin recorrente de células T maduras e células NK
- Micose Fungóide Recorrente
- Linfoma não Hodgkin cutâneo primário recorrente de células T
- Linfoma folicular grau 1 refratário
- Linfoma folicular grau 2 refratário
- Linfoma folicular grau 3a refratário
- Linfoma Não Hodgkin de Células T Maduras e Células NK Refratário
- Estágio IB Micose Fungóide AJCC v7
- Estágio II Micose Fungóide AJCC v7
- Linfoma não Hodgkin cutâneo de células T estágio III
- Estágio III Micose Fungóide AJCC v7
- Linfoma não Hodgkin cutâneo de células T estágio IV
- Estágio IV Micose Fungóide AJCC v7
- Linfoma Folicular Recorrente de Células T Auxiliares, Tipo Angioimunoblástico
- Linfoma Folicular Helper Refratário de Células T, Tipo Angioimunoblástico
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
PRIMARY OBJECTIVE:
I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of anti-ICOS monoclonal antibody MEDI-570 (MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), follicular lymphoma, mycosis fungoides (MF) and cutaneous T-cell lymphomas (CTCL).
SECONDARY OBJECTIVES:
I. To evaluate the pharmacokinetic profile of MEDI-570. II. To evaluate the overall response rate (ORR) and progression free survival (PFS) of MEDI-570 at all dose levels and in a 10-patient expansion cohort at the maximum tolerated dose (MTD).
III. To determine short and long term effects of MEDI-570 at all dose levels on the immune system and on T-cell lymphocyte subsets.
IV. To determine the relationship between ICOS expression on tumor cells and response to MEDI-570.
EXPLORATORY OBJECTIVE:
I. To evaluate biomarkers of response and resistance to MEDI-570 in the study population.
OUTLINE: This is a dose-escalation study.
Patients receive anti-ICOS monoclonal antibody MEDI-570 intravenously (IV) over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 6 weeks for 12 weeks.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 4E6
- BCCA-Vancouver Cancer Centre
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
-
-
California
-
Duarte, California, Estados Unidos, 91010
- City of Hope Comprehensive Cancer Center
-
Sacramento, California, Estados Unidos, 95817
- University of California Davis Comprehensive Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Yale University
-
New Haven, Connecticut, Estados Unidos, 06510
- Smilow Cancer Center/Yale-New Haven Hospital
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago Comprehensive Cancer Center
-
-
Kansas
-
Fairway, Kansas, Estados Unidos, 66205
- University of Kansas Clinical Research Center
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- University of Kentucky/Markey Cancer Center
-
-
Missouri
-
Creve Coeur, Missouri, Estados Unidos, 63141
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Estados Unidos, 63129
- Siteman Cancer Center-South County
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68198
- University of Nebraska Medical Center
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263
- Roswell Park Cancer Institute
-
The Bronx, New York, Estados Unidos, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Estados Unidos, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Duke University Medical Center
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Houston, Texas, Estados Unidos, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Pathologic diagnosis of one of the following:
-
For dose escalation:
-
Confirmed diagnosis of peripheral T-cell lymphoma (PTCL) or angioimmunoblastic T-cell lymphoma (AITL) that is refractory to at least one line of therapy; anaplastic large cell lymphoma (ALCL) and natural killer T-cell lymphoma nasal type (NKTCL) are excluded
-
Advanced stage cutaneous T-cell lymphoma (CTCL), specifically CTCL NOS, small/medium T-cell lymphoma (SMTCL) and mycosis fungoides (MF) stage IB, IIA, IIB, III and IV that have relapsed after at least one specific prior therapy (e.g. interferon, photopheresis, denileukin difitox, bexarotene, etc); anaplastic cutaneous large cell lymphoma (ACLCL) and lymphomatoid papulopsis are excluded
-
Follicular lymphoma grade 1, 2 or 3A that meets the following criteria:
- Relapsed or refractory to at least 2 lines of therapy AND
- Relapsed or refractory post autologous cell transplantation (HCT)
-
-
For dose expansion/dose confirmation phase:
- Patients with confirmed diagnosis of peripheral T-cell lymphoma (PTCL) follicular type or angioimmunoblastic T-cell lymphoma (AITL) that is refractory to at least one line of therapy
-
-
At least 14 days from the last therapy dose or 5 half-lives (whichever is shorter), and resolution of toxicity related to the last therapy, excluding grade 2 or less peripheral neuropathy and alopecia; for radiation therapy, a minimum of 2 weeks and resolution of all acute toxicity will be required
-
Patients must have at least one measurable lesion that can be accurately measured with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, or physical exam (by calipers only); (PTCL, AITL and follicular lymphoma patients will be assessed on this study using the Lugano criteria for the evaluation of lymphomas; CTCL and MF patients will be assessed using International Society for Cutaneous Lymphomas [ISCL] and European Organization for Research and Treatment of Cancer [EORTC] criteria)
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
-
Life expectancy of greater than 6 months
-
Leukocytes >= 3,000/mcL
-
Hemoglobin >= 80 d/L (or >= 8 g/dL)
- Patients must not have received a transfusion, with packed red blood cells, within 2 weeks prior to sample being collected
-
Absolute neutrophil count (ANC) >= 1,500/mcL
-
Platelets (PLT) >= 50,000/mcL
-
Absolute CD4 count > 100 cells/uL
-
Total bilirubin < 1.5 upper limit of normal (ULN)
-
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normal
-
Creatinine < 1.5 mg/dl (= 132 umol/L) or
-
Creatinine clearance >= 50 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
-
In patients with bone marrow involvement the minimum requirement is as follows:
- Leukocytes >= 2000/mcL
- ANC >= 1000/mcL
- PLT >= 50 000/mcL
-
Availability of tissue for correlative studies; patients must have at least 6-8 unstained slides of archived formalin-fixed, paraffin-embedded tumor tissue available; if not enough archived tissue is available, a fresh tumor biopsy prior to study initiation is mandatory; for patients who have undergone a fresh baseline biopsy at baseline, the archived tissue is not mandatory
-
The effects of MEDI-570 on the developing human fetus are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study participation, and for 3 months after the last dose of the drug; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must have either had a prior vasectomy or agree to use effective contraception prior to the study, during the study, and for 3 months after the last dose of the drug; males should avoid fathering children during and for at least three months after therapy is completed
-
Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
-
Patients who are receiving any other investigational agents
-
Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI-570 or history of anaphylaxis to any biological component
-
Any history or evidence of opportunistic infection within 6 months of screening including tuberculosis, severe cytomegalovirus (CMV) or herpetic infections (such as disseminated herpes, herpes encephalitis, ophthalmic herpes)
-
Evidence of active infection by hepatitis B and/or C; active viral infection by hepatitis B and hepatitis C could be associated with cytopenias (due to hypersplenism or due to the active virus itself), which could add further risk when a potential immunosuppressive medication is used; for patients with hepatitis B treated with anti-virals to undetectable viral load, and for patients with hepatitis C with undetectable ribonucleic acid (RNA) levels and no evidence of liver damage, enrollment may be considered and should discuss first with study's principal investigator
-
History of human immunodeficiency virus (HIV) infection; the human immunodeficiency virus (HIV) depletes CD4 T-cells and could also have a role in T-cell anergy; since MEDI-570 preferentially affects CD4 T-cell numbers and function, and the resultant immunosuppression by this agent can be prolonged, exposing HIV patients to MEDI-570 will place them in an unnecessary risk of developing infections due to an underlying acquired cellular immunity defect
-
History of primary immunodeficiency
-
Receipt of live or live attenuated vaccine within 12 weeks prior to enrollment
-
All potential patients must undergo a tuberculosis (TB) test prior to study entry to rule out active or latent tuberculosis (either purified protein derivative [PPD] or QuantiFERON-TB Gold, whichever is preferred and available at the institution); patients with a history of TB (even if treated), or evidence of active or latent TB, are excluded; the diagnosis of active TB is defined per current guidelines; patients with a positive TB test (e.g. PPD or QuantiFERON-TB Gold) will be excluded; patients with history of Bacille-Calmette-Guerin (BCG) vaccination will be tested with QuantiFERON-TB Gold test in order to rule out exposure to TB
-
Patients who have undergone allogeneic stem cell transplantation
-
Patients who have undergone autologous stem cell transplantation within 3 months from study entry
-
Major surgery within 30 days prior or during the study period
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Pregnant women are excluded from this study due to the potential toxicity in pre-clinical reproductive studies; in addition, there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MEDI-570; breastfeeding should be discontinued if the mother is treated with MEDI-570
-
Patients with active, known, or suspected autoimmune disease, except in these conditions:
-
Participants with well-controlled asthma and/or mild allergic rhinitis (seasonal allergies) are eligible
-
Participants with the following disease conditions are also eligible:
- Vitiligo,
- Type 1 diabetes mellitus
- Residual hypothyroidism due to autoimmune condition only requiring hormone replacement
- Euthyroid participants with a history of Grave's disease (participants suspected autoimmune thyroid disorders must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating immunoglobulin prior to first dose of study drug)
- For patients with ITP (idiopathic thrombocytopenic purpura) or AIHA (autoimmune hemolytic anemia), a case by case discussion with study principal investigator (PI) may be considered
- Patients not receiving systemic therapy (i.e., systemic steroids or biologic therapy with disease modifying anti-rheumatic drugs [DMARDs]) within 2 years can be also eligible
-
-
Patients with a weight of < 39 kg
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Treatment (MEDI-570)
Patients receive anti-ICOS monoclonal antibody MEDI-570 IV over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. |
Correlative studies Correlative studies Given IV
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of toxicity and safety of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
Prazo: Up to 12 weeks after completion of study treatment
|
Graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Frequency and severity of adverse events will be tabulated using counts and proportions detailing frequently occurring, serious and severe events of interest. Adverse events will be summarized using all adverse events experienced, although a sub-analysis may be conducted including only those adverse events in which the treating physician deems possibly, probably or definitely attributable to one or both study treatments. |
Up to 12 weeks after completion of study treatment
|
|
Maximum tolerated dose (MTD) of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
Prazo: Up to 21 days
|
Toxicity will be assessed using the NCI CTCAE, version 5.0. |
Up to 21 days
|
|
Recommended phase 2 dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
Prazo: Up to 21 days
|
Toxicity will be assessed using the NCI CTCAE, version 5.0. |
Up to 21 days
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pharmacokinetics (PK), such as plasma concentration and PK parameters, of monoclonal antibody therapy
Prazo: Prior to dose on day 1, immediately after dose, and at 6 minutes, 24, 48 and 72 hours post dose of cycle 1 and cycle 2, and then on day 1 pre-dose of every subsequent cycle
|
Attempts to model associations between pharmacokinetic data with toxicity profiles will be performed primarily using descriptive statistics; however, logistic regression may be used if warranted. |
Prior to dose on day 1, immediately after dose, and at 6 minutes, 24, 48 and 72 hours post dose of cycle 1 and cycle 2, and then on day 1 pre-dose of every subsequent cycle
|
|
Overall response rate
Prazo: Up to 36 weeks
|
Assessed per the Revised Response Criteria for Malignant Lymphoma of the Lugano Classification. Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant. |
Up to 36 weeks
|
|
Progression-free survival
Prazo: Up to 12 weeks after completion of study treatment
|
Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant. |
Up to 12 weeks after completion of study treatment
|
|
Immunogenicity
Prazo: Up to 36 weeks
|
Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant. |
Up to 36 weeks
|
|
Overall survival (OS)
Prazo: Up to 12 weeks after completion of study treatment
|
Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant. |
Up to 12 weeks after completion of study treatment
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Biomarkers of response and resistance to anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
Prazo: Up to 36 weeks
|
Predictors of clinical outcomes will be investigated using logistic regression, Cox proportional hazards regression and/or generalized estimating equations as appropriate. Potential predictors include clinical predictors and molecular correlates. Descriptive statistics and plotting of data will also be used to better understand potential relationships. |
Up to 36 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Julio C Chavez, University Health Network Princess Margaret Cancer Center LAO
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Linfoma Não-Hodgkin
- Linfoma
- Doenças hemic e linfáticas
- Linfoma Folicular
- Linfoma de Células T
- Linfoma de Células T Cutâneo
- Micose Fungóide
- MEDI-570
Outros números de identificação do estudo
Outros números de identificação do estudo
- NCI-2015-01271
- UM1CA186644 (Concessão/Contrato do NIH dos EUA)
- NCI-2015-01271 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- PJC-021
- 9930 (Outro identificador: CTEP)
- 9930 (Outro identificador: University Health Network Princess Margaret Cancer Center LAO)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .